Semax Structure And Research Background — Practical Notes

By Editorial Desk · published 2026-02-12 · last reviewed 2026-03-02 · Data

This is a working overview of synthetic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-03-02. Anything still debated is marked as such rather than presented as settled.

Semax Structure and Research Background

Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.

Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.

Semax Peptide Structure and Origin

The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.

Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.

Semax at a glance

Chemical Identity and Research Background

Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.

Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.

Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.

Related pages on this site

• Seasonal notes
• Smart digest
• Durable summary
• Scalable casebook
• Standard comparison
• Optimized handbook
• Clear checklist
• Modern primer

Semax Background and Chemistry

Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.

The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.

Reference notes

The recruitment of soldiers seemed to end up as a common pool employed by opposing sides as cannon fodder. Socially, both apparently opposing positions, loyalist and pro-independence, had an uncertain significance for the different social strata of the monarchy. In Europe, the Spaniards made a forced recruitment for the expeditionary forces, leading to constant rebellions. Independent states relied on privateers, mercenaries, volunteers, adventurers, or filibusters, reliable fighters when pay or booty was at a glance. For the mobilization of the population in the Americas, the vast majority or almost all of the troops of both sides, the indiscriminate recruitment of native American communities was used, in general in traditional confronted regions; social improvements were promised, by both sides, to the indigenous and the different mestizo colonial castes, such as mulattoes ("pardos"), cholos, etc., and even African slaves were recruited by both sides. All those recruited in the Americas, and also the Spaniards, joined the enemy armies as combatants when they were captured. Likewise, the Creole potentates of European origin could give their support to the royalist or pro-independence cause, in relation to the commercial interests of each region. The Church was also divided, and except for the lower clergy, who were involved as combatants of insurgency, their position was in accordance with the political power.

=== Transporter/receptor classification === GluT type: these express glutamate transporters (EAAT1/SLC1A3 and EAAT2/SLC1A2) and respond to synaptic release of glutamate by transporter currents. The function and availability of EAAT2 is modulated by TAAR1, an intracellular receptor in human astrocytes. GluR type: these express glutamate receptors (mostly mGluR and AMPA type) and respond to synaptic release of glutamate by channel-mediated currents and IP3-dependent Ca2+ transients.

=== Development === The episode was written by executive producer John Carcieri, executive producer Jeff Fradley, and series creator Danny McBride, and directed by executive producer Jody Hill. This was Carcieri's 19th writing credit, Fradley's 13th writing credit, McBride's 28th writing credit, and Hill's 14th directing credit.

=== China === In 2024, China’s supreme court and chief prosecutor jointly issued the Interpretation of Several Issues Concerning the Application of Law in Handling Criminal Cases of Money Laundering (2024). In American and British English, this title would translate to Money Laundering Prosecution Guidelines, and they explain how Criminal Law act section 191 applies to money laundering proceeds from specific unlawful activities. The guidelines treat money laundering done for concealment of criminal proceeds as a section 191 criminal offense both when tied to the offender’s own unlawful activity and when tied to unlawful activity committed by others, and directs courts to assess whether a defendant met a knowledge or reason-to-know standard based on totality-of-the-circumstances factors. The guidelines also identify aggravating circumstances where at least 5,000,000 yuan is laundered with specified sentencing enhancements, sets mandatory minimum fine amounts of 10,000 yuan for sentences up to five years imprisonment or jail and 200,000 yuan for sentences of five to ten years, superseding prior guidance from 2009 money laundering adjudicative guidelines. It is regulated by the China Anti-Money Laundering Monitoring and Analysis Center

Sources: en.wikipedia.org

Notes from published material

cis-regulatory element (CRE) Also cis-regulatory module (CRM). Any sequence or region of non-coding DNA which regulates the transcription of nearby genes (e.g. a promoter, operator, silencer, or enhancer), typically by serving as a binding site for one or more transcription factors. Contrast trans-regulatory.

Loss-of-function mutations, also called inactivating mutations, result in the gene product having less or no function (being partially or wholly inactivated). When the allele has a complete loss of function (null allele), it is often called an amorph or amorphic mutation in Muller's morphs schema. Phenotypes associated with such mutations are most often recessive. Exceptions are when the organism is haploid, or when the reduced dosage of a normal gene product is not enough for a normal phenotype (this is called haploinsufficiency). Examples of diseases caused by a loss-of-function mutation include Gitelman syndrome and cystic fibrosis. Gain-of-function mutations also called activating mutations, change the gene product such that its effect gets stronger (enhanced activation) or even is superseded by a different and abnormal function. When the new allele is created, a heterozygote containing the newly created allele as well as the original will express the new allele; genetically this defines the mutations as dominant phenotypes. Several of Muller's morphs correspond to the gain of function, including hypermorph (increased gene expression) and neomorph (novel function). Dominant negative mutations (also called anti-morphic mutations) have an altered gene product that acts antagonistically to the wild-type allele. These mutations usually result in an altered molecular function (often inactive) and are characterized by a dominant or semi-dominant phenotype.

==== Resignation ==== Cabinet met on the morning of Thursday 9 January, with Thatcher already having agreed her position with close colleagues at Chequers that weekend, and arranged that Scottish Secretary George Younger should take over as Defence Secretary if Heseltine resigned. Westland was first on the agenda, and Heseltine and Brittan were permitted to put their cases. Heseltine had won the moral high ground over the leaking saga, but Lawson recorded that he seemed obsessive at Cabinet and attracted little sympathy. Thatcher then reiterated her position, which had already been endorsed by the Cabinet, that Westland's future was a matter for Westland to decide, and announced that on grounds of Collective responsibility all answers to questions about Westland must in be cleared through the Cabinet Office. In response to a question by Nicholas Ridley (a friend of Heseltine) she confirmed that this also applied to statements which had already been made. Following further questions from Heseltine, and another summing up by Thatcher, Heseltine protested that there had been no collective responsibility, gathered up his papers and left the Cabinet Room. Eyewitness accounts differ as to his exact words, or even whether he explicitly resigned. By one account he declared, "I can no longer be a member of this Cabinet." Having allegedly paid a quick visit to the lavatory to straighten his hair and his Guards tie, Heseltine announced his resignation to the waiting press outside Number Ten, the first Cabinet minister to resign from a Cabinet meeting since Joseph Chamberlain in 1886.

Single-domain antibodies have been tested as a new therapeutic tool against multiple targets. In mice infected with influenza A virus subtype H5N1, nanobodies directed against hemaglutinin suppressed replication of the H5N1 virus in vivo and reduced morbidity and mortality. nanobodies targeting the cell receptor binding domain of the virulence factors toxin A and toxin B of Clostridioides difficile were shown to neutralize cytopathic effects in fibroblasts in vitro. Nanobody conjugates recognizing antigen presenting cells have been successfully used for tumor detection or targeted antigen delivery to generate strong immune response. Orally available single-domain antibodies against E. coli-induced diarrhoea in piglets have been developed and successfully tested. Other diseases of the gastrointestinal tract, such as inflammatory bowel disease and colon cancer, are also possible targets for orally available single-domain antibodies. Detergent-stable species targeting a surface protein of Malassezia furfur have been engineered for use in anti-dandruff shampoos. As an approach for photothermal therapy nanobodies binding to the HER2 antigen, which is overexpressed in breast and ovarian cancer cells, were conjugated to branched gold nanoparticles (see figure). Tumor cells were destroyed photothermally using a laser in a test environment. Caplacizumab, a single-domain antibody targeting von Willebrand factor is in clinical trials for the prevention of thrombosis in patients with acute coronary syndrome.

Horses are used to measure distances in horse racing – a horse length (shortened to merely a length when the context makes it obvious) equals roughly 8 feet or 2.4 metres. Shorter distances are measured in fractions of a horse length; also common are measurements of a full or fraction of a head, a neck, or a nose.

Sources: en.wikipedia.org

Frequently asked questions